 |
|
January 27, 2026 CMS Announces Selection of Drugs for the Third Cycle of the Medicare Drug Price Negotiation Program, Including First-Ever Selection of Drugs Payable under Part B Today, in accordance with section 1192 of the Social Security Act (the Act) and section 30 of the Medicare Drug Price Negotiation Program: Final Guidance, Implementation of Sections 1191 – 1198 of the Social Security Act for Initial Price Applicability Year 2028 and Manufacturer Effectuation of the Maximum Fair Price in 2026, 2027, and 2028 (“Final Guidance”), the Centers for Medicare & Medicaid Services (CMS) announced the selection of 15 drugs payable under Part B and/or covered under Medicare Part D for price negotiations for initial applicability year 2028. Between November 2024 and October 2025, about 1.8 million people with Medicare Part B and/or Part D coverage used these drugs to treat a variety of conditions, such as cancer and psoriatic arthritis. These selected drugs accounted for about $27 billion in prescription drug total expenditures under Medicare Part B and Part D, or about 6%, during that time period. The selected drug list for the third cycle of negotiations is:
In addition, CMS announced the selection of one drug chosen for renegotiation:
In accordance with the law, the negotiations with participating drug companies for these drugs will occur in 2026 and any negotiated and renegotiated prices will become effective in 2028. View a CMS fact sheet on the drugs selected for the Medicare Drug Price Negotiation Program at: https://www.cms.gov/files/document/factsheet-medicare-negotiation-selected-drug-list-ipay-2028.pdf. More information on the Medicare Drug Price Negotiation Program is available at https://www.cms.gov/priorities/medicare-prescription-drug-affordability/overview/medicare-drug-price-negotiation-program. For questions, please contact IRARebateandNegotiation@cms.hhs.gov. |
| Centers for Medicare & Medicaid Services (CMS) has sent this update. To contact Centers for Medicare & Medicaid Services (CMS) go to our contact us page. |
|